

AVENTIS PHARMA GMBH

1999/Z003 - Ma 1201 - C35

Claims for USA:

1. Modified Factor VIII cDNA, **characterised in** that the B-domain of the wild-type Factor VIII cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in one or more locations of the Factor VIII cDNA.
2. Modified Factor VIII cDNA as claimed in claim 1, **characterised in** that the B-domain of the wild-type Factor VIII cDNA has been replaced by four arginines.
3. Modified Factor VIII cDNA as claimed in claim 1, **characterised in** that the truncated Factor IX intron 1 has been inserted in the Factor VIII introns 1 and/or 12 and/or 13.
4. Modified Factor VIII cDNA as claimed in claim 2, **characterised in** that the truncated Factor IX intron 1 has been inserted in the Factor VIII introns 1 and/or 12 and/or 13.
5. Process for the production of Factor VIII, **characterised in** that the production is performed in a cell-line containing a modified Factor VIII cDNA as claimed in claim 1.
6. Transfervector for use in the human gene therapy, **characterised in** that it comprises the modified Factor VIII cDNA of claim 1.

ADD
B1

09880887 061504